EA202090757A1 - T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 - Google Patents
T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53Info
- Publication number
- EA202090757A1 EA202090757A1 EA202090757A EA202090757A EA202090757A1 EA 202090757 A1 EA202090757 A1 EA 202090757A1 EA 202090757 A EA202090757 A EA 202090757A EA 202090757 A EA202090757 A EA 202090757A EA 202090757 A1 EA202090757 A1 EA 202090757A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mutant
- cell receptors
- mammal
- disclosed
- methods
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
- A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
Раскрыт выделенный или очищенный T-клеточный рецептор (TCR), обладающий антигенной специфичностью в отношении мутантного человеческого p53. Также предложены родственные полипептиды и белки, а также родственные нуклеиновые кислоты, рекомбинантные экспрессионные векторы, клетки-хозяева, популяции клеток и фармацевтические композиции. Также раскрыты способы выявления наличия рака у млекопитающего и способы лечения или предупреждения рака у млекопитающего.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762565383P | 2017-09-29 | 2017-09-29 | |
PCT/US2018/051285 WO2019067243A1 (en) | 2017-09-29 | 2018-09-17 | T CELL RECEPTORS RECOGNIZING P53 MUTE |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090757A1 true EA202090757A1 (ru) | 2020-08-21 |
Family
ID=63714167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090757A EA202090757A1 (ru) | 2017-09-29 | 2018-09-17 | T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 |
Country Status (15)
Country | Link |
---|---|
US (1) | US11939365B2 (ru) |
EP (1) | EP3688027A1 (ru) |
JP (2) | JP7324193B2 (ru) |
KR (1) | KR20200064110A (ru) |
CN (1) | CN111386282A (ru) |
AU (1) | AU2018342246A1 (ru) |
BR (1) | BR112020006012A2 (ru) |
CA (1) | CA3077024A1 (ru) |
CR (1) | CR20200170A (ru) |
EA (1) | EA202090757A1 (ru) |
IL (1) | IL273515A (ru) |
MA (1) | MA50651A (ru) |
MX (1) | MX2020003504A (ru) |
SG (1) | SG11202002636PA (ru) |
WO (1) | WO2019067243A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3551221T3 (pl) | 2016-12-08 | 2022-02-28 | Immatics Biotechnologies Gmbh | Nowe receptory komórek t i immunoterapia z ich zastosowaniem |
WO2020237368A1 (en) * | 2019-05-27 | 2020-12-03 | Provincial Health Services Authority | Immunotherapy constructs targeting kras antigens |
JP2022538148A (ja) * | 2019-06-27 | 2022-08-31 | アメリカ合衆国 | p53におけるR175H又はY220C変異を認識するT細胞受容体 |
CN113512124A (zh) * | 2020-04-10 | 2021-10-19 | 香雪生命科学技术(广东)有限公司 | 一种识别hpv16的高亲和力tcr |
CA3191186A1 (en) * | 2020-09-04 | 2022-03-10 | Sanghyun Kim | T cell receptors recognizing r273c or y220c mutations in p53 |
JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
CN117957245A (zh) * | 2021-05-07 | 2024-04-30 | 美国政府(由卫生和人类服务部的部长所代表) | 识别p53中的c135y、r175h或m237i突变的t细胞受体 |
WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
US20240035027A1 (en) * | 2022-05-04 | 2024-02-01 | University Of Massachusetts | Oligonucleotides for pms2 modulation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770749B2 (en) * | 2000-02-22 | 2004-08-03 | City Of Hope | P53-specific T cell receptor for adoptive immunotherapy |
US7456263B2 (en) * | 2001-06-05 | 2008-11-25 | Altor Bioscience Corporation | P53 binding T cell receptor molecules |
EP1545204B1 (en) | 2002-09-06 | 2016-08-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
CA2920147C (en) * | 2013-08-07 | 2022-09-20 | Yeda Research And Development Co. Ltd. | Peptides capable of reactivating p53 mutants |
MX369513B (es) * | 2014-02-14 | 2019-11-11 | Univ Texas | Receptores de antígenos quiméricos y métodos de realización. |
JP2017514471A (ja) * | 2014-04-23 | 2017-06-08 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | キメラ抗原受容体(car)並びにその製造及び使用方法 |
LT3149031T (lt) | 2014-05-29 | 2020-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T ląstelių receptoriai prieš žmogaus papilomos virusą 16 e7 |
CN107074932A (zh) * | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法 |
AU2014407540C1 (en) | 2014-10-02 | 2021-07-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation |
EP3265079A4 (en) | 2015-03-03 | 2019-01-02 | Caris MPI, Inc. | Molecular profiling for cancer |
CA2984234C (en) * | 2015-05-01 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
CR20200476A (es) | 2015-05-20 | 2020-12-02 | Dana Farber Cancer Inst Inc | ANTÍGENOS COMPARTIDOS (Divisional 2017-0584) |
-
2018
- 2018-09-17 US US16/651,242 patent/US11939365B2/en active Active
- 2018-09-17 JP JP2020517556A patent/JP7324193B2/ja active Active
- 2018-09-17 EP EP18780006.5A patent/EP3688027A1/en active Pending
- 2018-09-17 WO PCT/US2018/051285 patent/WO2019067243A1/en active Application Filing
- 2018-09-17 KR KR1020207012344A patent/KR20200064110A/ko not_active Application Discontinuation
- 2018-09-17 MX MX2020003504A patent/MX2020003504A/es unknown
- 2018-09-17 SG SG11202002636PA patent/SG11202002636PA/en unknown
- 2018-09-17 CA CA3077024A patent/CA3077024A1/en active Pending
- 2018-09-17 CR CR20200170A patent/CR20200170A/es unknown
- 2018-09-17 EA EA202090757A patent/EA202090757A1/ru unknown
- 2018-09-17 MA MA050651A patent/MA50651A/fr unknown
- 2018-09-17 AU AU2018342246A patent/AU2018342246A1/en active Pending
- 2018-09-17 CN CN201880074539.8A patent/CN111386282A/zh active Pending
- 2018-09-17 BR BR112020006012-7A patent/BR112020006012A2/pt unknown
-
2020
- 2020-03-23 IL IL273515A patent/IL273515A/en unknown
-
2023
- 2023-07-28 JP JP2023123893A patent/JP2023159112A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020006012A2 (pt) | 2020-10-06 |
JP7324193B2 (ja) | 2023-08-09 |
KR20200064110A (ko) | 2020-06-05 |
JP2023159112A (ja) | 2023-10-31 |
SG11202002636PA (en) | 2020-04-29 |
CR20200170A (es) | 2020-11-23 |
US20200277352A1 (en) | 2020-09-03 |
IL273515A (en) | 2020-05-31 |
US11939365B2 (en) | 2024-03-26 |
CA3077024A1 (en) | 2019-04-04 |
CN111386282A (zh) | 2020-07-07 |
EP3688027A1 (en) | 2020-08-05 |
JP2021500010A (ja) | 2021-01-07 |
WO2019067243A1 (en) | 2019-04-04 |
MA50651A (fr) | 2020-08-05 |
MX2020003504A (es) | 2020-09-14 |
AU2018342246A1 (en) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090757A1 (ru) | T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 | |
EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
EA202090652A1 (ru) | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras | |
AU2019283892A1 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
MX2018003062A (es) | Receptores de celula t que reconocen kras mutante restringido en hla-cw8. | |
MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
MX2017006865A (es) | Receptores de células t de kras anti-mutado. | |
MX2021015877A (es) | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. | |
MX2024001190A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2023002858A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
BR112018075649A2 (pt) | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo | |
CA2848209C (en) | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage | |
WO2019002444A9 (en) | NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME | |
PH12018501335A1 (en) | Novel generation of antigen-specific tcrs | |
MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2022007902A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
MX2018012550A (es) | Composiciones y metodos para la deteccion de proteinas de celulas huesped. | |
MX2022010157A (es) | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. | |
MX2022009825A (es) | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. | |
FI3380115T3 (fi) | Peptidejä piwil1:stä | |
EA202192726A1 (ru) | Magea1-специфические т-клеточные рецепторы и их использование | |
WO2016077525A3 (en) | Human anti-thyroglobulin t cell receptors | |
BR112022006177A2 (pt) | Kir3dl3 é um receptor inibidor do sistema imune e do mesmo | |
MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
WO2022051449A3 (en) | T cell receptors recognizing r273c or y220c mutations in p53 |